1.1. Aims and Objectives
The European Association of Urology (EAU) Sexual and Reproductive Health Guidelines aim to provide a comprehensive overview of the medical aspects relating to sexual and reproductive health in adult men. These Guidelines cover the former EAU Guidelines on Male Sexual Dysfunction, Male Infertility and Male Hypogonadism.
It must be emphasised that guidelines present the best evidence available to the experts. However following guideline recommendations will not necessarily result in the best outcome. Guidelines can never replace clinical expertise when making treatment decisions for individual patients, but rather help to focus decisions - while taking personal values and preferences/individual circumstances of patients into account. Guidelines are not mandates and do not purport to be a legal standard of care.
1.2. Panel Composition
The EAU Sexual and Reproductive Health Guidelines Panel consists of an international multi-disciplinary group of urologists, endocrinologists and a psychologist. All experts involved in the production of this document have submitted potential conflict of interest statements which can be viewed on the EAU website:
1.3. Available Publications
Alongside the full text version, a quick reference document (Pocket Guidelines) is available in print and as an app for iOS and android devices. These are abridged versions that may require consultation together with the full text version. All documents can be viewed through the EAU website:
1.4. Publication History
This document is a further update of the 2021 Guidelines which already included a comprehensive update of the 2018 versions of Male Sexual Dysfunction, Male Infertility and Male Hypogonadism guidelines, along with several new topics. Additional sections will be added in the coming years to address male contraception, vasectomy, and penile cosmetic surgery, which have not previously been addressed.
1.5. Changes in the Guideline for 2022
The literature for the complete document has been assessed and updated, wherever relevant. Key changes in the 2022 publication:
- Section 3.4 - Classification and causes of male hypogonadism: update on effects of coronavirus 2 (SARS-CoV-2) infection (COVID-19);
- Section 22.214.171.124.1 – Treatment of Erectile Dysfunction - Platelet Rich Plasma: addition to the text and a new recommendation;
- Section 126.96.36.199.4 - Treatment of Premature Ejaculation – Tramadol: amendment to the text and amended recommendation;
- Section 188.8.131.52 - Conservative Treatment of Penile Curvature - Platelet Rich Plasma (PRP): addition to the text and new recommendation;
- Section 10.3 – Diagnostic Evaluation of Male Infertility: the text has been amended in light of the 6th edition of the WHO Manual for the Examination and Processing of Human Semen;
- Section 10.6.2 Male Infertility - Non-obstructive azoospermia: text and recommendation amended for indications and techniques of sperm retrieval relating to conventional and microdissection TESE.